Log in

NASDAQ:ONVO - Organovo Stock Price, Forecast & News

$0.29
0.00 (0.00 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$0.27
Now: $0.29
$0.30
50-Day Range
$0.21
MA: $0.30
$0.36
52-Week Range
$0.19
Now: $0.29
$1.05
Volume384,399 shs
Average Volume556,796 shs
Market Capitalization$37.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.99
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Read More
Organovo logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 million
Book Value$0.30 per share

Profitability

Net Income$-26,640,000.00
Net Margins-798.68%

Miscellaneous

Employees70
Market Cap$37.78 million
Next Earnings Date6/1/2020 (Estimated)
OptionableOptionable

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.


Organovo (NASDAQ:ONVO) Frequently Asked Questions

How has Organovo's stock been impacted by COVID-19 (Coronavirus)?

Organovo's stock was trading at $0.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONVO stock has increased by 11.3% and is now trading at $0.2895. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Organovo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Organovo.

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The medical research company had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 69.36%. View Organovo's earnings history.

Has Organovo been receiving favorable news coverage?

Press coverage about ONVO stock has trended somewhat negative on Saturday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Organovo earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOrganovo.

Are investors shorting Organovo?

Organovo saw a increase in short interest in March. As of March 13th, there was short interest totaling 2,286,300 shares, an increase of 14.9% from the February 27th total of 1,990,000 shares. Based on an average daily trading volume, of 404,600 shares, the days-to-cover ratio is presently 5.7 days. Approximately 1.8% of the shares of the company are short sold. View Organovo's Current Options Chain.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

Who are Organovo's key executives?

Organovo's management team includes the following people:
  • Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
  • Mr. Craig Kussman, Chief Financial Officer (Age 60)
  • Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Paul Gallant, Gen. Mang. (Age 54)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (14.95%), Renaissance Technologies LLC (5.38%), Essex Investment Management Co. LLC (1.01%) and UBS Group AG (0.07%). View institutional ownership trends for Organovo.

Which major investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Organovo.

Which major investors are buying Organovo stock?

ONVO stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Renaissance Technologies LLC, and ARK Investment Management LLC. View insider buying and selling activity for Organovo.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $0.29.

How big of a company is Organovo?

Organovo has a market capitalization of $37.78 million and generates $3.09 million in revenue each year. Organovo employs 70 workers across the globe. View additional information about Organovo.

What is Organovo's official website?

The official website for Organovo is http://www.organovo.com/.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


MarketBeat Community Rating for Organovo (NASDAQ ONVO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Put Option Volume

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel